ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE

Michelle Petri1, Laurence Magder 2 and Daniel Goldman 3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland School of Medicine, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antiphospholipid antibodies, hydroxychloroquine and prednisolone, prednisone, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels of their antiphospholipid antibodies. We examined the effect of prednisone and hydroxychloroquine on antiphospholipid antibodies in an SLE longitudinal cohort.

Methods: 943 SLE patients, who were tested for each anticardiolipin isotype (aCL IgG, IgM and IgA; INOVA) and lupus anticoagulant (dRVVT with further confirmatory testing) for at least 10 quarterly clinic visits, were included. We compared visits positive for antiphospholipid antibodies to visits negative for antiphospholipid antibodies, with respect to treatment, using conditional logistic regression and conditioning on the patient.

Results: The effect of prednisone on anticardiolipin and dRVVT > 45 (with further confirmatory testing) is shown in Table 1. The effect of hydroxychloroquine is shown in Table 2.

Conclusion: Prednisone does not reduce IgM or IgA isotypes of anticardiolipin, or lupus anticoagulant. These results explain why prednisone does not reduce thrombosis in SLE. Hydroxychloroquine, on the other hand, significantly reduces all antiphospholipid types except for the IgA isotype of anticardiolipin. This may explain why IgA isotypes are more common in SLE. It may also explain why hydroxychloroquine leads to only a 50% reduction in thrombosis, as IgA isotypes do confer some risk of thrombosis.


ACR 2019-Effect of Treatment on Antiphospholipid Antibodies in SLE-Table1

Odds ratio of having an antiphospholipid antibody on visits with various levels of prednisone compared to visits without prednisone


ACR 2019-Effect of Treatment on Antiphospholipid Antibodies in SLE-Table2

Odds ratio of having antiphospholipid antibodies on visits with hydroxychloroquine compared to visits without hydroxychloroquine


Disclosure: M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5; L. Magder, None; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Magder L, Goldman D. Effect of Treatment on Antiphospholipid Antibodies in SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-treatment-on-antiphospholipid-antibodies-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-treatment-on-antiphospholipid-antibodies-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology